Rna Diagnostics announces the publication of a study on February 24 2016 in the journal BMC Cancer entitled RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines. The study concludes that RNA disruption, as assessed by the RNA Disruption Assay™ (RDA™), is an effective biomarker to assess response to chemotherapy drugs in vitro and in vivo. RDA™ is the product of Rna Diagnostics Inc.
“This is the first paper to describe, in a compelling way, the mechanism for RNA disruption and that RNA disruption leads to cell death,” said Dr. Ken Pritzker, President and CEO of Rna Diagnostics Inc.
Supporting the previous clinical evidence, results from this study demonstrate that RNA disruption is induced by multiple classes of chemotherapy agents and is associated with drug response in cell lines from different tissues. Further studies are ongoing to understand RNA disruption as a distinct phenomenon and to unveil the specific cellular pathways associated with it. Given RNA disruption’s ability to serve as a novel biomarker to assess response to chemotherapy drugs in vitro and in vivo, RDA™ has the potential to help speed up the drug discovery process.
“These cell line findings support the data obtained from clinical studies in cancer patients. We continue to build on our understanding of the mechanism of RNA disruption. The findings in cell lines described in the BMC Cancer study give us greater confidence that the RNA Disruption Assay™ (RDA™) will provide meaningful data on tumour chemotherapy response in patients to enable clinicians to make treatment decisions with confidence,” said Dr. Amadeo Parissenti, Chief Scientific Officer of Rna Diagnostics.
To read the study please click here.
BMC Cancer is an open access, peer-reviewed journal publishing articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers.
About Rna Diagnostics Inc.
Rna Diagnostics is a cancer diagnostics company providing a platform of prognostic biomarker tools to help improve the lives of cancer patients treated with chemotherapy. Founded in 2010, Rna Diagnostics’ first product is The RNA Disruption Assay™ (RDA™) providing physicians with an evaluation of how individual patients are responding to chemotherapy as early as 14 days after 1stcycle of treatment. If chemotherapy is working, the physician and patient can continue treatment with confidence. If chemotherapy is not working, physicians may consider alternate therapies. For patients, this means avoiding harmful side effects and the possibility for improved survival outcomes. www.rnadiagnostics.com.